Xeris Biopharma (NASDAQ:XERS) Insider Sells $147,900.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 17,400 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00. Following the completion of the sale, the insider directly owned 1,393,653 shares of the company’s stock, valued at approximately $11,846,050.50. The trade was a 1.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS traded up $0.57 during trading on Tuesday, hitting $8.94. The company had a trading volume of 3,479,668 shares, compared to its average volume of 1,914,952. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of 149.00 and a beta of 0.62. The stock has a fifty day simple moving average of $6.65 and a two-hundred day simple moving average of $6.64. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.66 and a fifty-two week high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.80.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Xeris Biopharma by 21.8% during the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock worth $5,072,000 after acquiring an additional 156,483 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after acquiring an additional 225,602 shares during the last quarter. California State Teachers Retirement System lifted its stake in Xeris Biopharma by 19.3% in the 1st quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after purchasing an additional 29,168 shares in the last quarter. Royal Bank of Canada lifted its stake in Xeris Biopharma by 12.9% in the 1st quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after purchasing an additional 4,974 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Xeris Biopharma by 59.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after purchasing an additional 27,003 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.